Analysis
Five initial public offerings priced within roughly the same two-week window this month, and they landed nowhere near the same result. Ligent Technologies rose as much as 19.2% on its Hong Kong debut. Electra Therapeutics closed its first day down 12%. NSE India listed up just 0.84% before slipping below its issue price the following day. ADARx Pharmaceuticals priced its upsized offering at the top of its range. Bamboo Insurance pulled its NYSE listing entirely on pricing day. There is no single "2026 IPO market" story in that list -- there are five individual deal stories.
- Ligent Technologies -- priced at HKD 32.96, rose as much as 19.2% on its Hong Kong debut; the Qingdao-based, San Jose-headquartered optical-module maker sells gear for AI data-center networks and is controlled by China's Hisense Group. Pulse previously covered the pricing.
- Electra Therapeutics -- upsized $350 million offering priced at $15, the midpoint of its $14-$16 range, then closed its first trading day down 12%. Pulse previously covered the debut.
- NSE India -- an entirely offer-for-sale listing valuing the exchange around $46 billion, up just 0.84% on debut before trading below its issue price a day later. Pulse previously covered the listing.
- ADARx Pharmaceuticals -- priced its upsized offering at the top of its indicated range, one of the stronger pricing outcomes of the group.
- Bamboo Insurance -- pulled its NYSE listing on pricing day itself, despite CVC backing and an entirely secondary offer structure.
Sector, Not Timing, Is Doing The Work
All five deals priced within roughly the same fortnight, in the same broadly favorable 2026 IPO market that has raised $146.5 billion across 109 deals so far this year. The dispersion in outcomes says the market is now discriminating hard by story and sector rather than rewarding IPOs broadly: Ligent's genuine AI-data-center-infrastructure exposure cleared the bar convincingly, while Bamboo's more conventional insurtech positioning couldn't clear its order book at all in the same week, and Electra's rare-disease biopharma story wasn't enough to hold a midpoint price through a single trading day.
What Breaks The Old Heuristic
For years, pricing at the top of the range was the reliable tell for a hot deal, and a midpoint print signaled banker caution. Electra broke that pattern this week -- a midpoint price followed by a 12% decline suggests either the range itself was mispriced or that day-one institutional demand has become less predictable than the pricing process assumes. Bankers advising the next wave of fall listings, including Oura's expected September 29 pricing, are working with a noisier signal than they had earlier this year.
What To Watch
Oura is the next real test case: it carries genuine AI-adjacent health-data framing and disclosed real revenue near $2 billion, closer to Ligent's profile than Electra's. How it prices, and how it trades on day one, will say more about which side of this week's split verdict is the actual trend, and Firmus's roughly $5 billion ASX listing in October gives investors a second, non-US data point on whether AI-infrastructure exposure keeps commanding a premium outside the American market too.